http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
베체트병 환자에서 혈청 대식세포 유주 억제 인자 (Macrophage Migration Inhibitory Factor, MIF)의 상승
김성동 ( Sung Dong Kim ),김상현 ( Sang Hyon Kim ),김해림 ( Hae Rim Kim ),박미경 ( Mi Kyung Park ),윤종현 ( Chong Hyeon Yoon ),김완욱 ( Wan Uk Kim ),이상헌 ( Sang Heon Lee ),박성환 ( Sung Hwan Park ),조철수 ( Chul Soo Cho ),김호연 대한류마티스학회 2004 대한류마티스학회지 Vol.11 No.3
Objective: Macrophage migration inhibitory factor (MIF) has emerged recently as an important regulator of inflammatory and immune responses. This work was undertaken to evaluate serum levels of MIF and in vitro MIF production by whole blood cells in patients with Behcet`s disease and investigate the relationship between serum levels of MIF and clinical manifestations. Methods: Sixty-five patients with Behcet`s disease and forty-eight healthy controls were studied to evaluate serum levels of MIF. Six patients with Behcet`s disease and Five healthy controls were studied for evaluating the production of MIF by whole blood cells. Serum and culture supernatant levels of MIF were measured by enzyme-linked immuno-sorbent assay (ELISA). The production of MIF by whole blood cells was investigated by culturing peripheral blood cells in the absence or presence of Concanavalin A (Con A). Results: Serum levels of MIF were higher in patients with Behcet`s disease than in healthy controls. Serum levels of MIF were changed in each patient with Behcet`s disease according to clinical disease activity (higher at active state). The MIF production by Con A-stimulated peripheral blood cell culture was higher in patients with Behcet`s disease than in healthy controls. Conclusion: Circulating levels of MIF are higher in patients with Behcet`s disease than in healthy controls and the levels of MIF may be associated with clinical disease activity. MIF may play an important role as a mediator of inflammation in Behcet`s disease and provide opportunity for the development of anti-MIF strategy for the treatment of patients with Behcet`s disease.
노인 및 시각 장애인도 사용 가능한 PDA 기반 출결 정보 관리
박성환(Sung-Hwan Park),길기범(Gi-Beom Kil),김종완(Jong-Wan Kim),강신재(Sin-Jae Kang) 한국멀티미디어학회 2008 한국멀티미디어학회 학술발표논문집 Vol.2008 No.1
본 연구에서는 일반인뿐만 아니라 노인이나 시각 장애인도 사용하기 편리한 PDA를 활용한 출결 정보 관리 시스템을 제안한다. 사용자가 등록한 정보에 따라 사용자를 3부류로 나누고 부류별로 데이터베이스를 구축하고, 사용자의 PDA 사용 수월성에 연동하여 출결 관리 프로그램을 이용 가능하도록 사용자 중심으로 개발한다. 생성된 사용자 작업 데이터베이스의 PC와 PDA간의 동기화 및 백업 기능을 구현하여 정보의 손실 정도를 낮추며, 음성정보를 지원하여 이해도를 높인다. 노인 및 시각장애인을 위한 PDA 기반 정보 서비스 프로그램을 개발함으로써 정보약자도 사용하기 편리한 모바일 서비스 프로그램의 가능성을 보여준다.
Association of Sacroiliac MR Findings with Disease Activity in Patients with Ankylosing Spondylitis
이상헌 ( Sang Heon Lee ),지원희 ( Won Hee Jee ),김완욱 ( Wan Uk Kim ),민준기 ( Jun Ki Min ),홍연식 ( Yeon Sik Hong ),박성환 ( Sung Hwan Park ),조철수 ( Chul Soo Cho ),김호연 ( Ho Youn Kim ) 대한내과학회 1999 대한내과학회 추계학술대회 Vol.57 No.-
전신성 홍반성 루푸스 환자의 임신이 태아와 산모에 미치는 영향 및 관련된 인자에 관한 연구
김완욱 ( Wan Uk Kim ),민준기 ( Jun Ki Min ),권낙기 ( Nak Ki Kwun ),박성환 ( Sung Hwan Park ),홍연식 ( Yeon Sik Hong ),이상헌 ( Sang Heon Lee ),조철수 ( Chul Soo Cho ),김호연 ( Ho Youn Kim ) 대한류마티스학회 1997 대한류마티스학회지 Vol.4 No.2
Objective: To analyze the effect of clinical and serological variables of SLE on pregnancy outcome and to analyze the effects of pregnancy on the disease course of SLE. Methods: We studied retrospectively about 91 pregnancies in 41 female patients with SLE, who had visted to Kangnam St Mary Hospital from January, 1990 to May, 1996. We divided the patients into two groups, who had been pregnant before SLE was established versus who were pregnant after SLE had been established. We considered the former as control group. We compared the fetal or maternal outcomes after divided the latter into subgroups according to our purposes such as cases with lupus flare versus without lupus flare, autoantibody (+) cases versus (-) cases, cases with renal disease versus without renal disease. Results: The rate of fetal loss, prematurity was 19.7%, 46.9% respectively in 63 cases of 32 patients who were pregnant after SLE had been estabished. The number of pregnancy loss and premature delivery was higher in pregnancy after SLE was established than before SLE was established. Lupus flare was associated with the positivity of antibody to ds DNA and negativity of antibody to Ro. The frequency of fetal loss was higher in pregnancies of antiphospholipid (+) women than those of antiphospholipid (-) women. Pregnancy with renal involvement was associated with short duration of gestation and small body weight of neonate. Conclusion: Lupus pregnancy remains highly risky from a maternal standpoint in terms of increased lupus activity and from fetal outcome standpoint in terms of fetal loss and preterm birth, especially in the antiphosphospholid positive mother.
혈관내피 성장인자를 차단하는 합성 펩타이드인 RRKRRR이 류마티스 염증반응에 미치는 영향
김완욱 ( Wan Uk Kim ),유승아 ( Seung Ah Yoo ),김해림 ( Hae Rim Kim ),박보형 ( Bo Hyoung Park ),민정요 ( Jeong Yo Min ),윤종현 ( Chong Hyeon Yoon ),박성환 ( Sung Hwan Park ),조철수 ( Chul Soo Cho ) 대한류마티스학회 2005 대한류마티스학회지 Vol.12 No.1
Objective: Vascular endothelial growth factor (VEGF) has been suggested to play a critical role in the pathogenesis of rheumatoid arthritis (RA). It has been demonstrated that synthetic arginine-rich hexapeptide, RRKRRR, shows significant inhibition of VEGF-induced angiogenesis, and also retarded the growth and metastasis of colon carcinoma cell by blocking the interaction between VEGF and its receptor. In this study, we investigated whether anti-VEGF RRKRRR peptide (dRK6) could regulate the activation of mononuclear cells of RA patients and suppress collagen-induced arthritis (CIA) in mice. Methods: Synovial fluid mononuclear cells (SFMC) or synoviocytes from RA patients were cultured in the presence of VEGF, and the levels of TNF-α and IL-6 were determined in the culture supernatants by ELISA. Blocking experiments were performed by adding dRK6 to thecells stimulated with VEGF. Additionally, the in vivo effect of dRK6 on the development of arthritis was tested in collagen induced arthritis (CIA) in DBA/1 mice. T cell responses to type II collagen (CII) and IgG antibodies to CII were examined in draining lymph node cells and sera of the mice, respectively. Results: dRK6 showed concentration-dependent inhibitory activity for the VEGF binding to its receptor on human vascular endothelial cells. The treatment of dRK6 completely abrogated the VEGF-induced productions of TNF-α and IL-6 by RA SFMC or synoviocytes. Moreover, a subcutaneous injection of dRK6 resulted in a dose-dependent decrease in the severity and incidence of CIA in mice. In these mice, the T cell responses to type II collagen (CII) in lymph node cells and circulating IgG antibodies to CII were also dose-dependently inhibited by the peptides. Conclusion: We observed firstly that anti-VEGF dRK6 blocked the VEGF-induced production of pro-inflammatory cytokine from RA SFMC and synoviocytes, and suppressed the ongoing paw inflammation in mice. These data suggest that dRK6 may be an effective strategy in the treatment of RA, and could be applied to modulate various chronic VEGF-dependent inflammatory diseases.